JAIME PAULA PESSOA LINHARES FILHO

(Fonte: Lattes)
Índice h a partir de 2011
3
Lattes
Projetos de Pesquisa
Unidades Organizacionais

Filtros

Limpar filtros

Configurações

Autor e Coautores FMUSP-HC Normalizados: CIBELE LARROSA GARZILLO ×

Resultados de Busca

Agora exibindo 1 - 10 de 19
  • conferenceObject
    EFFECT OF MYOCARDIAL ISCHEMIA IN DIABETIC AND NON-DIABETIC PATIENTS: LONG-TERM FOLLOW-UP OF MASS REGISTRY
    (2020) CARVALHO, Felipe Pereira Camara de; HUEB, Whady; LIMA, Eduardo Gomes; LINHARES FILHO, Jaime; RIBEIRO, Matheus; MARTINS, Eduardo; BATISTA, Daniel Valente; GARZILLO, Cibele; BOROS, Gustavo Andre Boeing; REZENDE, Paulo; RIBAS, Fernando Faglioni; SERRANO, Carlos; RAMIRES, Jose; KALIL-FILHO, Roberto
  • conferenceObject
    Application of SYNTAX score I, II and residual SYNTAX as predictors of long-term clinical outcomes after coronary artery bypass grafting
    (2019) MARTINS, E. B.; HUEB, W.; LIMA, E. G.; REZENDE, P. C.; GARZILLO, C. L.; CARVALHO, G. F.; CARVALHO, F. P. C.; LINHARES FILHO, J. P. P.; BATISTA, D. V.; SILVA, R. R.; BOROS, G. A. B.; AZEVEDO, D. F. C.; SERRANO JUNIOR, C. V.; RAMIRES, J. A. F.; KALIL FILHO, R.
  • conferenceObject
    Impact of chronic kidney disease on diabetic patients with stable coronary disease undergoing surgery, angioplasty or medical treatment in a ten-year follow-up
    (2018) BATISTA, D. V.; HUEB, W.; LINHARES FILHO, J. P. P.; SILVA, R. R.; LIMA, E. G.; REZENDE, P. C.; MARTINS, E. B.; GARZILLO, C. L.; AZEVEDO, D. F. C.; RAMIRES, J. A. F.; KALIL FILHO, R.
  • article 0 Citação(ões) na Scopus
    Effect of diabetic kidney disease on therapeutic strategies for coronary artery disease: ten year follow-up
    (2021) BATISTA, Daniel Valente; HUEB, Whady; LIMA, Eduardo Gomes; REZENDE, Paulo Cury; GARZILLO, Cibele Larrosa; GARCIA, Rosa Maria Rahmi; LINHARES FILHO, Jaime Paula Pessoa; MARTINS, Eduardo Bello; SERRANO JUNIOR, Carlos Vicente; RAMIRES, Jose Antonio Franchini; KALIL FILHO, Roberto
    Background: The best treatment for coronary artery disease (CAD) in patients with type 2 diabetes (DM2) and chronic kidney disease is unknown. Methods: This retrospective study included MASS registry patients with DM2 and multivessel CAD, stratified by kidney function. Primary endpoint was combined of mortality, myocardial infarction, or additional revascularization. Results: Median follow-up was 9.5 years. Primary endpoint occurrences among strata 1 and 2 were 53.4% and 40.7%, respectively (P=.020). Mortality rates were 37.4% and 24.6% in strata 1 and 2, respectively (P<.001). We observed a lower rate of major adverse cardiovascular events (MACE) (P=.027 for stratum 1 and P<.001 for stratum 2) and additional revascularization (P=.001 for stratum 1 and P<.001 for stratum 2) for those in the surgical group. In a multivariate analysis, eGFR was an independent predictor of MACE (P=.034) and mortality (P=.020). Conclusions: Among subjects with DM2 and CAD the presence of lower eGFR rate was associated with higher rates of MACE and mortality, irrespective of treatment choice. CABG was associated with lower rates of MACE in both renal function strata. eGFR was an independent predictor of MACE and mortality in a 10-year follow-up.
  • conferenceObject
    Effect of myocardial ischemia in diabetic and non-diabetic patients: long-term follow-up of MASS registry
    (2020) CARVALHO, F. Camara De; HUEB, W.; LIMA, E. G.; LINHARES FILHO, J. P. P.; RIBEIRO, M. O. L.; MARTINS, E. B.; V, D. Batista; GARZILLO, C. L.; RIBAS, F. F.; BOROS, G. A. B.; REZENDE, P. C.; V, C. Serrano Junior; RAMIRES, J. A. F.; KALIL FILHO, R.
  • conferenceObject
    VERY LONG-TERM FOLLOW-UP OF DIABETIC PATIENTS WITH CORONARY ARTERY DISEASE UNDERGOING ANGIOPLASTY WITH CONVENTIONAL AND DRUG-ELUTING STENTS
    (2019) MOCHA, Mauricio; RIBEIRO, Matheus Oliveira Laterza; CARVALHO, Guilherme Fernandes; LINHARES FILHO, Jaime; LIMA, Eduardo; HUEB, Whady; REZENDE, Paulo; BATISTA, Daniel Valente; MARTINS, Eduardo; AZEVEDO, Diogo Freitas Cardoso; GARZILLO, Cibele; KALIL-FILHO, Jose Ramires Roberto
  • conferenceObject
    Impact of glycated hemoglobin in diabetic patients with coronary artery disease undergoing surgery, angioplasty or clinical treatment in a very long-term follow-up
    (2018) LINHARES FILHO, J. P. P.; HUEB, W.; BATISTA, D. V.; SILVA, R. R.; LIMA, E. G.; REZENDE, P. C.; MARTINS, E. B.; GARZILLO, C. L.; AZEVEDO, D. F. C.; RAMIRES, J. A. F.; KALIL FILHO, R.
  • conferenceObject
    Cardiac Biomarkers Elevation After Myocardial Revascularization Predicts Cardiovascular Prognosis. Long-Term Follow-Up of Mass-V Study
    (2018) LINHARES FILHO, Jaime P.; HUEB, Whady; V, Daniel Batista; LIMA, Eduardo G.; SILVA, Rafael R.; REZENDE, Paulo C.; STRUNZ, Celia M.; MARTINS, Eduardo B.; GARZILLO, Cibele L.; AZEVEDO, Diogo F.; DALLAZEN, Anderson R.; RIBAS, Fernando F.; RAMIRES, Jose A.; KALIL FILHO, Roberto
  • conferenceObject
    Impact of Syntax Score on Release of Cardiac Biomarkers in Post-revascularization Procedures Among Patients With Stable Multivessel Disease: Mass-v Insights
    (2017) AZEVEDO, Diogo F.; HUEB, Whady; TAKIUTI, Myrthes E.; LIMA, Eduardo G.; REZENDE, Paulo C.; GARZILLO, Cibele L.; SEGRE, Carlos A.; LINHARES FILHO, Jaime P.; GARCIA, Rosa M.; NOMURA, Cesar H.; RAMIRES, Jose A.; KALIL FILHO, Roberto
  • article 14 Citação(ões) na Scopus
    Long-term outcomes of patients with stable coronary disease and chronic kidney dysfunction: 10-year follow-up of the Medicine, Angioplasty, or Surgery Study II Trial
    (2020) LIMA, Eduardo Gomes; CHARYTAN, David M.; HUEB, Whady; AZEVEDO, Diogo Freitas Cardoso de; GARZILLO, Cibele Larrosa; FAVARATO, Desiderio; LINHARES FILHO, Jaime Paula Pessoa; MARTINS, Eduardo Bello; BATISTA, Daniel Valente; REZENDE, Paulo Cury; HUEB, Alexandre Ciappina; RAMIRES, Jose Antonio Franchini; KALIL FILHO, Roberto
    Background. Chronic kidney disease (CKD) is associated with a worse prognosis in patients with stable coronary artery disease (CAD); however, there is limited randomized data on long-term outcomes of CAD therapies in these patients. We evaluated long-term outcomes of CKD patients with CAD who underwent randomized therapy with medical treatment (MT) alone, percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG). Methods. Baseline estimated glomerular filtration rate (eGFR) was obtained in 611 patients randomized to one of three therapeutic strategies in the Medicine, Angioplasty, or Surgery Study II trial. Patients were categorized in preserved renal function and mild or moderate CKD groups depending on their eGFR (>= 90, 89-60 and 59-30 mL/min/1.73 m(2), respectively). The primary clinical endpoint, a composite of overall death and myocardial infarction, and its individual components were analyzed using proportional hazards regression (Clinical Trial registration information: http://www.controlled-trials.com.Registration number: ISRCTN66068876). Results. Of 611 patients, 112 (18%) had preserved eGFR, 349 (57%) mild dysfunction and 150 (25%) moderate dysfunction. The primary endpoint occurred in 29.5, 32.4 and 44.7% (P = 0.02) for preserved eGFR, mild CKD and moderate CKD, respectively. Overall mortality incidence was 18.7, 23.8 and 39.3% for preserved eGFR, mild CKD and moderate CKD, respectively (P = 0.001). For preserved eGFR, there was no significant difference in outcomes between therapies. For mild CKD, the primary event rate was 29.4% for PCI, 29.1% for CABG and 41.1% for MT (P = 0.006) [adjusted hazard ratio (HR) = 0.26, 95% confidence interval (CI) 0.07-0.88; P = 0.03 for PCI versus MT; and adjusted HR = 0.48; 95% CI 0.31-0.76; P = 0.002 for CABG versus MT]. We also observed higher mortality rates in the MT group (28.6%) compared with PCI (24.1%) and CABG (19.0%) groups (P = 0.015) among mild CKD subjects (adjusted HR = 0.44, 95% CI 0.25-0.76; P = 0.003 for CABG versus MT; adjusted HR = 0.56, 95% CI 0.07-4.28; P = 0.58 for PCI versus MT). Results were similar with moderate CKD group but did not achieve significance. Conclusions. Coronary interventional therapy, both PCI and CABG, is associated with lower rates of events compared with MT in mild CKD patients >10 years of follow-up. More study is needed to confirm these benefits in moderate CKD.